SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation

NewTimeSpace News: On 20 August 2026, SSY Group Limited (stock code: 02005) announced in a voluntary announcement that the Group has obtained the drug production registration certificate from China's National Medical Products Administration for Vitamin K1 Injection (1ml:10mg), classified as Chemical Drug Category 3 and deemed to pass the consistency evaluation.

According to the announcement, Vitamin K1 Injection is mainly used for the treatment of vitamin K deficiency bleeding and the prevention of vitamin K deficiency that cannot be addressed through nutritional supplementation; it is a basic clinical medication widely used for bleeding prevention and emergency treatment with a large market size, and the approval enriches the Group's injection product portfolio.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.